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Abstract
TrkB mediates the effects of brain-derived neurotrophic factor (BDNF) in neuronal and nonnneuronal cells. Based on recent
reports that TrkB can also be transactivated through epidermal growth-factor receptor (EGFR) signaling and thus regulates
migration of early neurons, we investigated the role of TrkB in migration of lung tumor cells. Early metastasis remains a
major challenge in the clinical management of non-small cell lung cancer (NSCLC). TrkB receptor signaling is associated with
metastasis and poor patient prognosis in NSCLC. Expression of this receptor in A549 cells and in another adenocarcinoma
cell line, NCI-H441, promoted enhanced migratory capacity in wound healing assays in the presence of the TrkB ligand
BDNF. Furthermore, TrkB expression in A549 cells potentiated the stimulatory effect of EGF in wound healing and in Boyden
chamber migration experiments. Consistent with a potential loss of cell polarity upon TrkB expression, cell dispersal and de-
clustering was induced in A549 cells independently of exogeneous BDNF. Morphological transformation involved extensive
cytoskeletal changes, reduced E-cadherin expression and suppression of E-cadherin expression on the cell surface in TrkB
expressing tumor cells. This function depended on MEK and Akt kinase activity but was independent of Src. These data
indicate that TrkB expression in lung adenoma cells is an early step in tumor cell dissemination, and thus could represent a
target for therapy development.
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Introduction
Lung cancer is the second most commonly diagnosed cancer
and the leading cause of cancer-related death among the
malignant tumors [1]. More than a million deaths per year are
due to lung cancer worldwide. Based on clinical pathology, 15–
20% of lung carcinomas are categorized as small-cell lung cancer
(SCLC) and 80–85% as non-small-cell lung cancer (NSCLC).
NSCLCs are further divided into three different histological
subtypes [2], adenocarcinoma (30–40%), squamous cell carcinoma
(20-25%) and large-cell carcinoma (15–20%). NSCLC is initiated
in lung cells by toxicity (e.g. from tobacco smoke) that causes
genetic alterations. Additional molecular changes in premalignant
cells result in advanced cancer and metastasis [3,4]. The primary
reason for the low cure rate from NSCLC is that about 70% of
patients present with advanced disease, after the formation of
metastatic spreading, and that even early stage NSCLC have a low
overall survival rate [5]. Whether the metastatic cells disseminated
from an aggressive NSCLC primary tumor at around the time of
advanced stage disease or by clonal outgrowth of dormant
micrometastatic cells that had dislodged from an early primary
tumor years before first disease symptoms is an unresolved
question [6]. In cases of advanced disease (spread to contralateral
and mediastinal lymph nodes or even distant metastases) systemic
chemotherapy is the main treatment.
Lung cancer progression depends on the capacity to invade and
to metastasize to distant sites. Tumor cell metastasis is thought to
be controlled by molecular processes that are different from those
which control tumor initiation and growth [7]. Support for this
hypothesis comes from the observation of human cancer lesions as
well as several mouse models in which tissue-specific oncogene
expression led to tumor initiation, yet tumor progression was not
observed [8,9]. The metastatic process is complex because it
involves several distinct steps such as tumor cell dispersal from the
epithelium, invasiveness, intravasation into lymph or blood vessels,
dissemination, and extravasation into a remote organ and
colonization of this organ [10].
Tropomyosin-related kinase TrkB (Ntrk2) and its ligand BDNF
play an instrumental role in nervous system development [11].
BDNF/TrkB signaling stimulates migration of cerebellar granule
cells and cortical neurons during development, and the absence of
TrkB signaling during embryonic cortical development causes a
delay in neuronal migration and thereby disturbes neuronal
stratification [12]. Acquired TrkB (over)expression has been
detected in various human cancers [13], including neuroblastoma
[14], pancreas [15], colon [16], stomach [17] and multiple
myeloma [18]. In a study on the expression of TrkB in NSCLC
[19] about two thirds of the patients showed elevated TrkB
expression. Notably, acquired expression of TrkB has been
associated with metastasis and poor patient prognosis in NSCLC
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[19,20] as well as in pancreas [15], gastric [17] and colon cancer
[16]. Non-synonymous point mutations in the kinase and
extracellular domains of TrkB have been found in several cancers,
including colon cancer [21] lung adenocarcinoma [22] and large
cell neuroendocrine carcinoma of the lung [23]. Because these
mutations were identified by large scale sequencing approaches of
cancer samples, the variant proteins could be either passenger or
driver mutations and the discrimination between these two
possibilities requires subsequent analysis of the transforming
activity of the protein variants. This evaluation has been done
recently for two of the TrkB mutations found in colon cancer, one
mutation found in a lung adenocarcinoma cell line [24] and three
mutations detected in large cell neuroendocrine carcinoma of the
lung [25]. The mechanism how these TrkB variants could
contribute to tumorgenicity remained unclear from these studies.
Previous studies to dissect the functional effects have shown that
forced expression of TrkB in rat intestinal epithelial cells conferred
anoikis resistance in vitro and allowed the TrkB expressing cells to
form tumors and metastases in nude mice [26,27]. Further
experiments using TrkB/BDNF expressing rat intestinal epithelial
cells demonstrated that TrkB/BDNF induced epithelial-mesen-
chymal transition (EMT) through regulation of E-cadherin
expression that required the transcription factor Zeb-1 in order
to suppress E-cadherin expression [28].
In this study we examined the effects of TrkB expression in two
human lung adenocarcinoma cell lines on fundamental properties
of metastatic cells, including cell migration, cell spreading and
invasiveness. We found that TrkB activation enhanced migration
and dispersal of these cells. TrkB was not only activated by BDNF,
but also could be transactivated by EGF receptor (EGFR)
signaling, as recently shown in early neurons that form the
cortical layers of the brain [29]. These data indicate that TrkB
could play a central role in early steps of metastasis.
Results
Expression of TrkB in lung tumor cells enhances cell
migration and wound closure
The overexpression of tropomyosin receptor kinase B has been
observed in several aggressive cancers, including NSCLC
[13,19,30]. Of note, TrkB expression correlated significantly with
metastasis and poor prognosis in NSCLC [19,20]. Furthermore,
TrkB was identified in an unbiased screen for genes that suppress
programmed cell death when epithelial cells were deprived from
attachment to extracellular matrix [26]. To examine whether and
how TrkB expression could support tumor cell dissemination and
metastatic progression in NSCLC, we used two distinct NSCLC
cell lines, A549 and NCI-H441. To mimic the in vivo situation, we
overexpressed TrkB in these cell lines. We cloned wild-type and, as
a negative control, kinase-inactive mutant TrkB (unable to bind
ATP [31]) into the retroviral pBABE-puro expression vector. We
transduced virus harbouring these TrkB vectors or empty vector
control virus independently into both lung cancer cell lines and
isolated under puromycin selection several independent individual
clones from each transduction. We confirmed by western blot
analysis that TrkB and kinase-dead TrkB proteins, respectively
were expressed in several independent A549 (Figure 1A) and NCI-
H441 (Figure 1B) clones at levels comparable to those observed in
mouse brain tissue. Empty vector clones did not reveal a Trk signal
indicating absence of endogenous TrkB expression. We thus
generated a cell system allowing us to evaluate the activities and
functions of TrkB expression in lung cancer cells.
In order to study the effects of TrkB expression on cell
migration, a scratch wound assay was used. Incubation of A549
empty vector or A549 cells expressing a kinase-dead TrkB showed
a modest effect on wound repair (around 10–15% wound closure
within 24 hours, Figure 1C and E) which was not significantly
increased by the addition of BDNF. This lack of response in clones
harbouring empty vector is expected because there was no Trk
expression detectable by Western blot analysis (Figure 1A). In
contrast, incubation of TrkB expressing cells with BDNF
stimulated lung cancer cell migration in the wound closure assay
(Figure 1C and E). Besides augmented wound closure, BDNF
addition to TrkB expressing cells but not to cells expressing kinase-
inactive TrkB, induced single cells or small cell clusters in the
wound area (Figure 1C and F). A significant stimulatory effect of
BDNF on wound closure was also observed in NCI-H441 clones
where the expression of TrkB enhanced BDNF-dependent cell
migration whereas clones carrying empty vector or expressing
kinase-dead TrkB showed a lower level of wound closure
(Figure 1D and G).
TrkB expression acts synergistically with EGF to stimulate
migration
Next, we tested the effect of EGF in the wound closure response.
We observed that TrkB expression significantly enhanced the
effect of EGF in wound repair, as compared to the stimulatory
effect of EGF in empty vector and TrkB (kinase-dead) cell clones
(Figure 2A and C). A significantly increased number of single cells
with spindle-like morphology was found in the wound area of
TrkB expressing cells treated with EGF (Figure 2B). TrkB
activation was analysed in extracts of A549 cells plated in
subconfluent conditions and treated with BDNF or EGF for 5
minutes. In response to BDNF, bands of 130 and 170 kD were
visible, as reported previously for neural cells [29]; these bands
were absent in empty vector transfected cells (Figure 2D). In the
absence of BDNF, the 170 KD band was weaker, while the
130 kD band was more intense. Cell extracts from TrkB
expressing cells treated with EGF also showed multiple bands,
including those of 130 and 170 kD; EGF addition to cells
harbouring empty vector also revealed a 140 kD band that was
absent in empty vector cell extracts not treated with growth factor
or treated with BDNF (Figure 2D).
To support the above findings from the wound closure assay, we
evaluated the migratory capacity of TrkB expressing cells in
Boyden chamber assays. As shown in Figure 3, A549 cells
expressing wild-type TrkB invaded through the collagen-coated
filters upon BDNF stimulation. It is of note, that the stimulatory
effect of EGF in transwell migration of A549 empty vector and
Trk-kinase-dead expressing cells was significantly enhanced by the
expression of TrkB (Figure 3). Thus, TrkB expression in A549 cells
did not only mediate increased migration upon stimulation with
BDNF, but in addition potentiated the action of EGF in wound
repair and transwell migration experiments.
TrkB expression mediates cell spreading
In order to further investigate the potential loss of cell polarity
upon TrkB expression (see Figure 2B), we plated lung tiu´mor cells
at moderate density (15.000 cells per cm2) on serum-coated plastic
or collagen I-coated surfaces. A549 cells formed compact colonies
24 hours after plating with a clustered cobblestone-like appear-
ance, typical for many epithelial cells cultured in the absence of
pro-inflammatory cytokines. This allowed us to study the effect of
TrkB on de-clustering and cell dispersal. A549 cell clones
expressing TrkB grown on a serum-coated cell culture-plastic
surface showed a dispersal and scattering of the compact colonies
with apparently reduced cell-cell contacts (Figure 4A and B). This
morphologic transformation was observed in the absence of BDNF
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Figure 1. Expression of TrkB in human adenocarcinoma cells enhances cell motility in wound closure. A, B. Immunoblot analysis of cell
lysates from A549 cell clones (A) or NCI-H441 cell clones (B) transduced with retrovirus harbouring empty vector or vector encoding TrkB and kinase-
dead TrkB (kd), respectively. TrkB expression was evaluated with a COOH-terminal (C14) pan-Trk antibody. Adult mouse brain cortex tissue served as
positive control. Gapdh served as a loading control. C, D. Wound closure assay demonstrating increased cell motility of A549 cells (C) or NCI-H441
cells (D) expressing TrkB. Cells were plated in 6-cm dishes and grown to 100% confluence. Plates with serum-starved confluent cells were scratched
with a pipette tip to create a single scratch wound, washed and cultured for another 24 h (A549 cells) or 20 h (NCI-H441 cells) in the absence or
presence of BDNF (10 ng/ml). Representative photographs were taken immediately after scratch injury and 20 h or 24 h later. Bar, 200 mm. E. Bar
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addition in independent clones expressing TrkB, and was neither
observed in the empty vector clones nor in the clones expressing
kinase-inactive TrkB (Figure 4A and B). In order to exclude the
possibility that unwanted alterations that inhibited declustering
had occurred in any of the cell clones during selection or
passaging, cells were also grown on fibronectin which leads to cell
dispersal and EMT in primary alveolar epithelial cells as reported
previously [32]. Culturing the cell clones on fibronectin revealed a
similar extent of cell dispersal in all clones arguing against
passaging-induced alterations (Figure 4A). A549 cell clones
expressing TrkB grown on a collagen I coated surface also showed
a dispersal of the compact colonies with apparently reduced cell-
cell contacts (Figure 4A and C). Notably, many individual TrkB
expressing cells grown on plastic/serum or collagen (Figure 4A)
showed a more elongated and sometimes even a spindle-shaped
morphology. The morphological transformation appeared as
robust as in human breast epithelial fibrocystic MCF10A cells,
but less pronounced than that observed in RIE-1 rat intestinal
epithelial and RK3 rat epithelial cells, where TrkB/BDNF
expression induced a strong EMT [33].
To elucidate the signaling pathways involved in cell spreading of
A549 cell clones expressing TrkB, cells were cultured in the
presence of inhibitors. Blockage of the Raf/MEK/ERK pathway,
or the Akt and Src kinases was achieved by the addition of 1 mM
PD0325901, 1 mM Akti-1,2, and 1 mM PP2, respectively. Empty
vector clones formed compact colonies without growth factor
addition and in the presence of BDNF, irrespective of the presence
of inhibitors (Figure 5). The addition of Akti-1,2 and PD0325901
suppressed the dispersal phenotype in TrkB expressing cells, and
the addition of BDNF did not alter the compact phenotype
(Figure 5), demonstrating that TrkB-induced cell dispersal is
reversible within 24 hours of growth and depends on Akt and
MEK kinase signaling pathways. The Src kinase inhibitor PP2 was
unable to ablate the dispersed morphology in TrkB expressing
cells.
Next, we examined the effect of EGF on cell spreading in TrkB
and empty vector cells. As expected, stimulation with 10 ng/ml
EGF for 24 hours induced cell spreading (Figure 5). In cells
harbouring empty vector, addition of PP2 and PD0325901
suppressed the EGF-induced morphological changes and the cells
displayed a clustered phenotype, whereas Akti-1,2 had no
significant influence on EGF-induced cell dispersal (Figure 5).
The de-clustering of TrkB expressing cells exposed to EGF was
unaffected by PP2 and Akti-1,2 but inhibited by PD0325901
(Figure 5). Thus, while TrkB requires Akt and MEK kinase to
induce de-clustering, the activation of EGF in combination with
TrkB expression relieves cells from dependence on Src and Akt. In
other words, whereas Src and MEK kinases were instrumental for
spreading of A549 cells in response to EGF, Src was no longer
required when TrkB was co-expressed.
TrkB expression causes disruption of membrane-
associated E-cadherin
Since expression of TrkB in A549 cells suppressed the formation
of clustered cells and thus deregulated their polarity, we asked
whether the strength of cell-cell contacts is also reduced after
elevated TrkB expression. Downregulation of E-cadherin expres-
sion is characteristic of early epithelial to mesenchymal transition
[34]. Thus, we investigated whether the level of E-cadherin in
TrkB expressing A549 clones was altered compared to control
clones harbouring empty vector. We determined the levels of
cadherin expression by western blotting of cell lysates prepared
from cells that showed dispersal, or no dispersal (TrkB expressing
cells treated with the MEK inhibitor PD0325901). Notably, E-
cadherin protein levels were reduced approximately twofold in
TrkB expressing cells, compared to cell clones harbouring empty
vector (Figure 6A). Treatment with PD0325901 restored the
expression of E-cadherin, in line with a switch from cell dispersal
to a compact cell morphology (see Figure 5). A similar level of
reduced E-cadherin expression was observed upon culture of TrkB
expressing cells in the presence of EGF.
In order to further delineate the mechanism of cell dispersal, we
investigated cytoskeletal changes and determined the subcellular
localization of E-cadherin. In control clones, E-cadherin was
localized along the intercellular surfaces, indicative of the existence
of E-cadherin-mediated interactions among neighbouring cells.
TrkB expressing clones showed a reduction of E-cadherin staining
at cell-cell contacts and an increased punctuate staining through-
out the cytoplasm suggesting that E-cadherin is either endocytosed
or not delivered to sites of cell-cell contacts (Figure 6B). Cells
cultured on a fibronectin substrate, which induced cell spreading
(see Figure 4A, right column) showed a similar pattern of internal
E-cadherin expression. The arrangement of the actin filaments,
visualized by phalloidin staining, revealed that TrkB expression
promoted extensive cytoskeletal changes (Figure 6B). A549 cells
carrying empty vector exhibited highly organized filamentous
actin immediately underneath the cell membrane. TrkB expres-
sion resulted in a redistribution of F-actin with evidence of F-actin
stress fibre formation (Figure 6B).
Discussion
We show here that forced expression of the TrkB receptor
kinase in two human lung adenocarcinoma cell lines, A549 and
NCI-H441, caused enhanced migratory capacity in the presence
of the TrkB ligand BDNF. Furthermore, TrkB expression in A549
cells potentiated the stimulatory effect of EGF in wound healing
and in Boyden chamber migration experiments. TrkB expression
conferred cell dispersal and de-clustering of A549 cell colonies that
did not require the addition of exogeneous BDNF and depended
on MEK and Akt kinase function but was independent of Src
signaling. This morphological transformation was found to
correlate with a reduction of E-cadherin expression and a
suppression of E-cadherin expression at the cell surface in cells
expressing TrkB. From these data we envision an in vivo scenario,
where lung adenoma cells would be able to dislodge from the
epithelium and become invasive once TrkB becomes expressed.
The failure of NSCLC therapy is mostly due to the development
of local and distant metastasis [35]. Dissemination of cells from the
primary tumor is considered a major step and requires loss of cell
contact to neighbour cells as a first step to escape the epithelium of
origin. A549 and NCI-H441 cells are a well established in vitro cell
system valuable to explore the transitions that occur during
NSCLC progression. Our observation that TrkB expression in
A549 cells induced cell dispersal and prevented the formation of
compact cell clusters in the absence of exogenous BDNF is novel.
The finding that TrkB expressing tumor cells showing cell
dispersal retained E-cadherin intracellularly is compatible with
observations from clinical carcinoma specimens [36]. Alternative-
ly, E-cadherin can be suppressed at the transcriptional level [33].
graphs show quantification of wound closure of A549 cell clones. F. Bar graphs show number of live cells of A549 cell clones in the wound area. G. Bar
graphs show quantification of wound closure of NCI-H441 cell clones. Bars, mean 6 SEM from three independent cell clones.
doi:10.1371/journal.pone.0100944.g001
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Maintenance of E-cadherin expression might actually provide an
opportunity for the migrating tumor cell to attach again in a new
location and form a micrometastasis when a suitable environment
is encountered. In A549 cells it has been shown, that FGF-1 could
restore E-cadherin expression and revert EMT induced by TGF-
b1 [37]. During the invasion and migration phases, TrkB provides
protection from anoikis [26]. The mechanism behind the cell
dispersal phenotype is unclear. It might involve activation of TrkB
by the EGFR, as shown for neural precursor cells [29].
Alternatively, transactivation of the EGFR is a well-known
mechanism that can occur either through non-receptor tyrosine
kinases or through EGFR ligand shedding mediated by metallo-
proteases [38].
The extent of cell dispersal induced by BDNF in epithelial cells
with ectopic TrkB expression was found to be variable in different
cell lines derived from intestine, kidney and breast [33].
Figure 2. TrkB expression acts synergistically with EGF to
stimulate migration. A. Wound closure assay demonstrating
increased cell motility of A549 cells expressing TrkB upon EGF
stimulation. Cells were plated in 6-cm dishes and grown to 100%
confluence. After generating a single scratch wound in the monolayer,
cells were washed and cultured for another 24 h, Representative
photographs were taken immediately after scratch injury and 24 h later.
Bar, 200 mm. Bar graphs show quantification of wound closure and
number of live cells in the wound area. Bars, mean 6 SEM (n= 6). Bar,
200 mm B. Higher magnification picture demonstrating the effect of
TrkB expression in response to EGF, note spindle-shaped morphology
of cells in the wound area in response to EGF. Bar, 200 mm C. Bar graphs
show quantification of wound closure in response ot EGF. Bars, mean6
SEM (n = 6). D. Phosphorylation of TrkB in response to BDNF and EGF.
Immunoblot analysis of equal amounts of cell lysates from A549 empty
vector (ev) and TrkB cell clones using a phospho-specific antibody that
recognizes phosphorylated tyrosines within the catalytic domain of
TrkB (pY674/pY675 in human TrkA). Gapdh served as a loading control.
doi:10.1371/journal.pone.0100944.g002
Figure 3. TrkB expression confers increased migration in
transwell assays. A549 cells (26104) suspended in culture media
were seeded in the upper chamber of transwell plates. After 18 h
incubation, cells that migrated to the lower surface of the filters were
fixed, stained with cresyl violet and quantiified by counting three
randomly selected fields using a 10x objective. Bar, 200 mm. Bars, mean
6 SEM.
doi:10.1371/journal.pone.0100944.g003
TrkB Enhances Dispersal and Migration of Lung Tumor Cells
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e100944
Furthermore, different conditions of cell culture such as cell
density may also affect the extent of cell dispersal. In contrast to
cell dispersal, cell migration required the addition of exogenous
BDNF to TrkB expressing lung tumor cells. The source of BDNF
may be the tumor microenvironment [39]. BDNF produced by
platelets [40] and/or endothelial cells [41] would be able to
stimulate the migratory capacity and survival of the detached
tumor cells.
A previous study noted the expression of TrkB in A549 cells [19]
but we were unable to detect endogenous Trk expression by
immunoblotting. Furthermore, the addition of BDNF did not
augment wound closure in A549 control cells harbouring empty
vector, indicating an absence of a positive effect of BDNF in wound
closure. As reported previously, A549 cells respond to EGF by
endocytosis of E-cadherin [42] and to TGF-b, a well-studied inducer
of EMT, by suppression of E-cadherin expression [43,44]. In our
study, the expression of TrkB had a comparable molecular effect on E-
cadherin in the absence of forced ligand expression or ligand addition.
Trk family members and their neurotrophin ligands regulate
neuronal survival, differentiation and migration as well as synaptic
plasticity [11]. In neuroblastoma, TrkB/BDNF expression is
preferentially found in aggressive tumors, whereas the expression
TrkA or TrkC is associated with better prognosis [45]. An
explanation for this different cellular response may be that TrkA
and TrkC, in contrast to TrkB, are dependence receptors that
instruct developing neurons to die in the absence of ligand [46].
TrkA expression indeed induced cell death of neuroblastoma cells
and required CCM2 as a primary effector [47].
Acquired TrkB (over)expression has been detected also in
various human epithelial cancers [13]. Higher expression levels of
TrkB have been found to be associated with aggressive tumor
behaviour and poor prognosis in several epithelial cancers,
including colon cancer [16], pancreatic cancer [15] and gastric
cancer [17]. In NSCLC, TrkB expression correlated with lymph
node metastasis [19], vascular invasion and poor disease-free and
overall survival [20].
Taken together, these data indicate that TrkB could be a
regulator of cell dispersal and migration and initiation of
metastasis in many types of epithelial tumors, thus resembling a
physiological function of this receptor in the developing brain.
TrkB is expressed in early neurons before they migrate out of the
subventricular zone in the cortical neuroepithelium towards the
mantle zone where these neurons then end their migration in the
cortical layers. Interestingly, this migration is dependent on TrkB
and the activation of this receptor [12,48], but does not depend on
the presence of BDNF, indicating that nonligand mediated
Figure 4. TrkB expression induces cell spreading dispersal. A. Morphology of A549 cell colonies and cell dispersal harbouring empty vector (e
vector), or expressing wild-type TrkB (wt) or kinase-dead TrkB (kd) plated on noncoated, collagen I or fibronectin-coated dishes. Phase contrast
pictures were taken using a 10x objective. Bar, 200 mm B. Bar graphs show quantification of colonies on non-coated dishes. Bars, mean6 SEM (n= 6).
C. Bar graphs show quantification of colonies on collagen I-coated dishes. Bars, mean 6 SEM (n= 6); (***, p,0.0002).
doi:10.1371/journal.pone.0100944.g004
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activation mechanisms are involved. Only later in development
after neuronal migration has been finished these cortical neurons
are activated by BDNF. This seems to be the case also for TrkB
expressing A549 cells which start to detach from the epithelial
structure by morphological transformation in a BDNF indepen-
dent manner, and subsequently respond to BDNF in their
migration. The initial start of migration depends on TrkB
activation, and it is highly suggestive that other signaling pathways
described previously to transactivate TrkB are involved, as
previously shown for early cortical neurons that start to migrate
[29]. These results indicate that interference with TrkB expression
and activation could be a means to inhibit dispersal and migration
Figure 5. TrkB expression induced cell spreading requires Akt and MEK kinase activity. Morphology of cell colonies and cell dispersal of
A549 cells harbouring empty vector (e vector) or expressing wild-type TrkB (wt). Cells were plated on noncoated dishes, grown for 24 hours in the
presence of 0.5% serum and subsequently stimulated with BDNF or EGF for a period of 24 hours in the presence or absence of Src inhibitor PP2, Akt
kinase inhibitor Akti-1,2 (Akti) or MEK inhibitor PD0325901 (PD); untreated cells were cultured in the presence of vehicle (v, 0.1% DMSO). Bar, 200 mm.
Bar graphs show quantification of colonies. Bars, mean 6 SEM (n= 3).
doi:10.1371/journal.pone.0100944.g005
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of these tumor cells and thus to prevent initiation of migration.
This could be a potential new approach for NSCLC therapy.
Materials and Methods
Cell culture
The human NSCLC cell line A549 (bronchioalveolar carcino-
ma, American Type Culture Collection, ATCC-CCL-185, [49])
was cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum and Pen/Strep; a
second human lung adenocarcinoma cell line NCI-H441 (ATCC-
HTB-174, [50]) was propagated in RPMI 1640 medium with 10%
FCS and Pen/Strep. Cells were cultured at 37uC, 5% CO2. Both
cell lines were subjected to DNA typing of short tandem repeats
and genotyped to ensure their identity (Leibniz-Institute DSMZ).
DMEM, RPMI-1640, FCS, Glutamax and Pen/Strep were
purchased from Life Technologies. All cells were cultured on
tissue culture-treated plastic and rat tail collagen I (50 mg/ml, BD
Biosciences) or fibronectin-coated (50 mg/ml, R&D Systems) glass,
respectively at 37uC and 5% CO2 atmosphere. For migration
assay, cells were made quiescent by culture in fresh medium
containing 0.5% serum for 1 day.
Generation of stable cell lines, plasmids and primers
Retrovirus was produced in HEK293T cells by transfection.
The pBABE-puro vector (Addgene #1764) contained the full
length murine TrkB cDNA. A point mutant (K571M, corre-
sponding to K560M in rat TrkB) encoding a kinase-inactive TrkB
[31] was constructed using a commercial kit (Agilent quickchange
II site-directed mutagenesis kit) according to the manufacturer’s
protocol. Oligonucleotides were as follows, sense, GATCCT-
GGTGGCTGTGATGACGCTGAAGGACGCC, and antisense,
GGCGTCCTTCAGCGTCATCACAGCCACCAGGATC. The
mutation was confirmed by sequencing.
Two million cells grown on a 10-cm dish were transfected using
Lipofectamin 2000 (Invitrogen) with 9 mg vector DNA, 8 mg
pUMV3a expression plasmid encoding gag/pol (Addgene #8449)
and 1 mg CMV-VSV-G plasmid (Addgene #8454). Cell culture
supernatant containing the retrovirus was harvested 60 h after
transfection, mixed with polybrene (10 mg/ml; Santa Cruz
Biotechnology), filtered through 0.45 mm filters and used for
transduction of A549 and NCI-H441 cells. Three days after
transduction, different aliquots of the cells were seeded and
puromycin (Santa Cruz Biotechnology) selection was begun
(2.5 mg/ml for A549 cells, and 1 mg/ml for NCI-H441 cells).
Individual colonies were isolated using cloning cylinders (Millipore).
Protein extraction and immunobloting
For Western blot analysis, cells were washed twice with
phosphate-buffered saline and protein was extracted with a lysis
buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
2 mM EDTA, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium
deoxycholate in the presence of proteinase inhibitors (cOmplete
Protease Inhibitor Cocktail, Roche) and a phosphatase inhibitor
cocktail (PhosSTOP, Roche). Cell extracts were clarified by
centrifugation at 20,0006g, and the supernatant was subjected to
protein content determination using a BCA protein assay kit
(Pierce). SDS/polyacrylamide gel electrophoresis and electroblot-
ting to nitrocellulose membranes (Whatman Protran BA83,
0,2 mm) were done as described [51]. The following antibodies
were used: rabbit anti-Trk (Santa Cruz Biotechnology, sc-11,
1:1.000); rabbit anti-phospho-TrkA (pTyr674/675) (Cell Signal-
ing, 4621, 1:1.000); rabbit anti E-cadherin (Cell Signaling 3195,
1:2.000); 1:2.000, mouse anti GAPDH (Calbiochem, CB1001,
1:3.000). The membranes were developed by chemiluminescence
detection using ECL or ECL prime (GE Healthcare) with a goat
horseradish peroxidase-conjugated secondary antibody. The
images were recorded on x-ray film and then scanned on a
flatbed scanner. Band intensities were quantified using Image J.
Cell aggregation and migration assays
For cell aggregation, cells were harvested from 80% confluent
cultures with trypsin and plated at a density of 15.000 cells/cm2 on
9-cm dishes (Nunc). After 24 h, the cultures were fed with new
medium containing 0.5% foetal calf serum and further cultured for
24 h. Then, inhibitors were added 1 h prior to stimulation with
growth factors, as indicated, and remained in the medium for the
remainder of the experiment. Akti-1,2, PD0325901 and PP2 were
purchased from Calbiochem and used at 1 mM. BDNF or human
EGF (Peprotech; 10 ng/ml) were added for evaluation of cell-
declustering and the culture was incubated for 24 h. Photographs
were taken (Nikon Eclipse TS100 inverted microscope equipped
with a 10x 0.24A phase contrast lens and a DS-2Mv camera). The
number of cell clusters with a diameter larger than 125 mm was
quantified; values are representative of at least 40 microscopic fields
(area 0.7946 mm2 each) from three independent experiments.
For wound healing, cells were seeded at a density of 1.5 Mio in
6-cm plates (BD Biosciences) until a confluent monolayer had
developed. At confluency, medium containing 0.5% foetal calf
serum was added to the cultures and incubation continued for
Figure 6. TrkB expression suppresses cell-surface expression of
E-Cadherin. A. Immunoblot analysis of cell lysates from A549 cell
clones stably expressing TrkB or harbouring empty vector, cultured on
plastic in the absence or in the presence of EGF (E), and with or without
the MEK inhibitor PD0325901 (PD), respectively. Expression levels of E-
cadherin were quantified by densitometric analysis and normalized by
comparison to the Gapdh loading control, shown for each lane as
values. B. Immunostaining of E-cadherin and F-actin. Cells were grown
on collagen I or fibronectin coated glass slides, serum deprived for
24 hours, fixed and stained. Nuclei were counterstained with DAPI.
Results are representative of more than three experiments.
doi:10.1371/journal.pone.0100944.g006
TrkB Enhances Dispersal and Migration of Lung Tumor Cells
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e100944
24 h, before being wounded with the use of a 200 ml pipette tip
that extended the full diameter of the dish. Detached cells were
removed from the cultures by two rounds of washing with HBSS,
followed by incubation with medium containing 0.5% foetal calf
serum supplemented with or without BDNF or EGF (10 ng/ml).
Images of the wound were photographed with a 10x lens
immediately following wounding and 20 h (for NCI-H441 cells)
or 24 h (for A549 cells) later. The number of phase-bright living
cells present in the wound was counted and the wound area in
each image was determined. Wound closure was quantified using
ImageJ by following the change in wound area over time. Values
are representative of between five and nine experiments.
Boyden chamber cell migration was carried out in transwell
plates (Corning, 24-well, 8 mm pore size). The upper surface of the
filter was precoated with collagen I (50 mg/ml). A549 cells were
grown to 70% confluency, followed by a 24 h culture in medium
containing 0.5% foetal calf serum. Cells were harvested with
trypsin and placed in the upper chamber at 20.000 cells in 200 ml
of medium containing 0.5% foetal calf serum. BDNF of EGF
(10 ng/ml) were used as chemoattractant in the lower chamber
filled with 600 ml medium containing 0.5% foetal calf serum, and
the cells were allowed to migrate for 12 hours. Cells that had
migrated onto the lower surface of the membrane were fixed with
4% (w/v) paraformaldehyde, stained with eosin, and quantified by
microscopy. At least three separate microscopic fields were
counted per filter.
Immunofluorescence microscopy
Cells were grown on cover glasses (10 mm diameter) coated
with rat tail collagen I (50 mg/ml) or fibronectin-coated (50 mg/ml)
in 4-well dishes (Nunc) at a density of 15.000 cells/cm2 under
conditions described above. Cells were fixed for 15 min with 4%
(w/v) paraformaldehyde, washed with PBS. After a 90-min
incubation with permeabilization buffer (PBS with 5% goat serum
and 0.3% Triton X-100), primary antibodies (mouse anti E-
Cadherin, BD Biosciences, 610181, 1:200) were added for
120 min. The cells were washed four times with wash buffer
(PBS with 0.2% Triton X-100 and 0.1% Tween 20) followed by
incubation with Alexa Fluor-488-labelled antibody (Invitrogen,
1:800). For F-actin staining, rhodamin-phalloidin (Cytoskeleton
Inc.) was used at a concentration of 70 nM. DAPI (1 mg/ml) was
used to counterstain cell nuclei. Images were obtained using a
confocal laser scanning microscope (Olympus FluoView FV1000
confocal LSM) equipped with a UPLFLN 40xO NA: 1.30 lens.
Images represent a single confocal section. Images were processed
with Image J.
Statistical analysis
One-way analysis of variance (ANOVA) was applied for the
comparison of samples. Data are presented as mean 6 standard
error of the mean (SEM). Statistical significance was assessed by
calculating the P values; P,0.05 was considered significant).
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